Get started
VERTEX PHARMDRNVERTEX PHARMDRNVERTEX PHARMDRN

VERTEX PHARMDRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

VRTX34 trade ideas

VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH (1/9) Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀 (2/9) – REVENUE RUSH • Q4 Haul: $ 2.91B—16% jump from last year 💥 • Full ‘24: $ 11.02B, up 12%—Trikafta’s king 📊 • ‘25 Outlook: $11.75-$ 12B—6-9% growth NYSE:CF keeps humming—newbies add zest! (3/9) – BIG WINS • Journavx: Non-opioid painkiller greenlit Jan ‘25 🌍 • Alyftrek: CF drug for 6+—ships now 🚗 • Cash: $11.2B—loaded for action 🌟 NASDAQ:VRTX storms pain—CF stays golden! (4/9) – SECTOR CHECK • Valuation: 11x sales—above 9x avg 📈 • Vs. Peers: Gilead’s 4x, Regeneron’s 8x—premium? • Growth: 12% beats biotech’s 5-7% 🌍 NASDAQ:VRTX flexes—value or stretch? (5/9) – RISKS ON TAP • Payers: Journavx needs coverage—hiccups? ⚠️ • Trikafta: 93% of sales—big lean 🏛️ • Comp: Pain rivals, CF safe—for now 📉 Hot streak—can it dodge the bumps? (6/9) – SWOT: STRENGTHS • CF King: Trikafta, Alyftrek lock it in 🌟 • Pain Play: Journavx eyes $ 4B peak 🔍 • Cash: $11.2B—war chest ready 🚦 NASDAQ:VRTX ’s got muscle and moolah! (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: Trikafta reliance—eggs in one basket 💸 • Opportunities: Casgevy rolls, pain grows 🌍 Can NASDAQ:VRTX zap past the risks? (8/9) – NASDAQ:VRTX ’s Q4 surge—what’s your vibe? 1️⃣ Bullish—Pain pays off big. 2️⃣ Neutral—Solid, but risks linger. 3️⃣ Bearish—Growth hits a wall. Vote below! 🗳️👇 (9/9) – FINAL TAKEAWAY NASDAQ:VRTX ’s $2.91B Q4 and Journavx/Alyftrek wins spark buzz—$11.2B cash backs it 🌍🪙. Trikafta rules, risks hover—champ or chaser?
NASDAQ:VRTXLong
by DCAChampion
Vertex Pharmaceuticals Pulls Back After RallyVertex Pharmaceuticals ended January with a big rally. Now, after a pullback, some traders may see an opportunity. The first pattern on today’s chart is the price gap on January 31 after the FDA approved its Journavx painkiller. (It’s the first of its kind to treat pain in a unique way without addiction risks.) The stock has retraced the surge, which may appeal to dip buyers. Second is the October 7 close of $448.60. VRTX held that level in late November and again on December 18 before gapping down. The stock is now trying to stabilize in the same location, suggesting support may remain in effect. Next, the MACD surge in January could reflect bullish short-term momentum. Prices are also trying to hold the rising 21-day exponential moving average. Finally, VRTX is near its 50-, 100- and 200-day simple moving averages. That may create potential for the longer-term trend to accelerate if the short-term strength continues. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NASDAQ:VRTX
by TradeStation
Can Pain Be Managed Without Addiction?Vertex Pharmaceuticals has achieved a monumental breakthrough in pain management, securing FDA approval for Journavx, the first new class of painkiller in over 20 years. This non-opioid drug introduces a paradigm shift, targeting pain signals directly at the source without the addictive risks associated with traditional analgesics. The significance of this development cannot be overstated, as it promises a new era where acute pain can be treated effectively and safely, potentially altering the landscape of medical treatment for millions. Journavx operates by selectively inhibiting NaV1.8, a sodium channel vital for pain signaling, thus preventing pain signals from reaching the brain. This mechanism not only offers relief but does so without the side effects that have long plagued opioid use. The implications for healthcare are profound, offering doctors and patients alike a tool that can redefine how we approach pain management in clinical settings. Vertex's success with Journavx showcases the company's commitment to pioneering treatments that address some of the most pressing needs in modern medicine. Financially, this approval has bolstered Vertex's market position, evidenced by a significant uptick in stock performance following the announcement. With a revenue projection for 2025 set between $11.75 and $12.0 billion, Vertex is not just riding the wave of this single approval but is also expanding its therapeutic horizons. The strategic leadership transitions announced alongside this approval signal a robust plan for future innovation, challenging investors and healthcare professionals to think about the evolving landscape of drug development and patient care.  This moment invites us to ponder the future of pharmaceuticals - one where efficacy does not compromise safety, where innovation in treatment could lead to broader societal benefits by reducing dependency on addictive substances. Vertex's journey with Journavx might just be the beginning of a new chapter in medical science, urging us to envision a world where pain management is humane and humane-centered.
NASDAQ:VRTXLong
by UDIS_View
Vertex Pharmaceuticals (VRTX) | Chart & Forecast SummaryRight Here You Can See Vertex Pharmaceuticals Incorporated (VRTX) Registered As (VRTX) On The New York Stock Exchange, Vertex Pharmaceuticals Incorporated Is An American Biopharmaceutical Company Based In Boston, Massachusetts. The Following Chart & Forecast Summary On Vertex Pharmaceuticals Incorporated (VRTX) Has been Subject On Key Indicators on A Trade Set Up in General Like A 1. A Push Set Up 2. A Range Set up 3. And A Break & Retest Set Up Overall Conclusion | Like The Trade Plan Execution & Risk Management on Demand It Tells Us "Long Bias For Now"
CAPITALCOM:VRTXLong
by TradePolitics
Vertex Pharmaceuticals pioneers with non-opioid painkiller VX-54Vertex Pharmaceuticals Inc., widely recognised for its cystic fibrosis treatments, is venturing into new therapeutic areas , signalling potential growth in new markets. The company is currently advancing its development of non-opioid analgesics, specifically candidate VX-548, which has demonstrated encouraging outcomes in clinical trials. This new drug represents a significant shift in pain management, offering an alternative to opioid medications. Vertex is preparing to seek FDA approval for VX-548 within the year. If approved, this drug could substantially impact the healthcare industry and is projected to achieve peak annual revenues of 5 billion USD – approximately half of Vertex's current annual revenue. Exploring investment opportunities, here is a technical analysis of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX): On the Daily (D1) timeframe, the stock exhibits a 410.00 USD resistance level and support at 392.00 USD. The stock is currently trending downward. Notably, there have been three consecutive trading sessions with a gap up, suggesting that major players might be accumulating buy positions. If the downtrend persists, the next price target could be around 360.50 USD. For traders, breaking the resistance at 410.00 USD could provide a buying opportunity, with a short-term target set at 421.00 USD. If the resistance is surpassed, holding a long position with a target of up to 436.50 USD might be considered for a medium-term strategy. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NASDAQ:VRTX
by RoboMarkets
VRTX Stock – the Alternative to OxyContin?In the wake of the opiod epidemic, brought on in part by the success of Oxycodone, a new exceptional drug is being developed by Vertex Pharmaceuticals (NASDAQ: VRTX). With the intention of providing relief from severe pain without the addictive properties of opioids, Vertex’s new drug could be on track to replicate the success of Oxycodone – making VRTX stock one to watch this year. It recently aced clinical trials, and as a result, the company is setting its sights on obtaining FDA approval for this revolutionary drug. If Vertex wins approval, it could add a massive $1 billion to its revenues each year from sales. This new drug could push Vertex to the forefront of the painkiller market and the pharmaceutical industry as a whole. But Vertex has a number of other catalysts that could propel Vertex Pharmaceuticals toward a multi-billion dollar future. VRTX’s Experimental Painkiller Vertex Pharmaceuticals is a biotech company specializing in developing and selling medications for treating cystic fibrosis, a life-threatening disease affecting the lungs and digestive tracts. The company’s treatments for this disease include best-selling drugs like Trikafta, which brought Vertex $6.6 billion in just the first nine months of 2023. Now, it’s making a significant move in the painkillers market and adding another game-changer to its product offerings. Recently, the company said that its experimental painkiller, which is being tested as an alternative to addictive opioids, significantly decreased post-surgery pain in late-stage trials. This new drug works by blocking pain signals at their origin before they reach the brain. In two late-stage studies on more than 1,000 patients, it was effective in reducing the intensity of pain after 48 hours. Thanks to this news, VRTX stock had a mini rally of 2%, and the price increased to around $435.82. Still, this was enough to outpace the flat-lining S&P 500. Even though it had impressive results, the drug, known as VX-548, didn’t work better than an opioid. But, with the opiod epidemic raising concerns for many Americans, Vertex could capitalize on the desire for an effective, and truly non-addictive painkiller. The Opioid Epidemic You probably know of Oxycodone, the most infamous opioid of all time. It was developed by a company called Purdue Pharma in the 1990s. The company promoted the opioid as a non-addictive drug, and Purdue Pharma incentivized many doctors to start prescribing Oxycodone to their patients across the USA. Sadly, many Amercians became addicted to the drug they were told was non-addictive, leading to widespread abuse of Oxycodone. As a result, Purdue Pharma made more than $31 billion from it as of 2016. But it came at a high price, in fact, 500,000 people died from overdosing on prescription and illicit opioids from 1999 to 2020. As you’d expect, Purdue Pharma was heavily criticized for its role in the epidemic. Purdue Pharma filed for bankruptcy in 2020, but oxycodone is still on the market leaving consumers and regulators are searching for a safer alternative to Oxycodone. This is where Vertex’s new painkiller steps in. VX-548’s Potential By the middle of this year, Vertex plans to file for FDA approval of VX-548 for the treatment of moderate-to-severe acute pain. This could be a game-changer for the company if it wins approval, and could also be a huge catalyst for VRTX stock. According to Wall Street analysts’ estimates, sales from VX-548 could exceed $1 billion if it gets FDA approval. Comparatively, Purdue Pharma made around $3 billion in revenue each year since 2002, mainly from sales of OxyContin. With time, VRTX could see similar revenue from sales of VX-548. Since the drug is not physically addictive like OxyContin, sales may never match that of Purdue Pharma’s, however its worth noting the impressive size of the pain relief market. Around 80 million patients are prescribed medicine for moderate-to-severe acute pain every year in the US and the chronic pain market is valued at more than $2.5 billion. According to estimates by RBC analysts, Vertex’s drug could earn between $300 to $400 million annually from this market. VRTX Stock Catalysts Besides VX-548, VRTX has two other catalysts that could make VRTX stock one to watch in 2024. The first is Exa-cel. In 2015, Vertex entered into a strategic research collaboration with CRISPR Therapeutics (NASDAQ: CRSP). Together, they developed Exa-cel, a gene-editing therapy for sickle cell disease and beta thalassemia. Fast forward to January of 2024, the FDA gave Exa-cel early approval, making it the first-ever gene therapy developed to treat rare blood disorders. But, the general public turned against the two companies as soon as they revealed Exa-cel’s price tag. It’s not unusual for gene therapy to be expensive, as the average cost of a gene therapy is between $1 million and $2 million per dose. Exa-cel’s price, however, is above the average at $2.2 million. Clearly, the vast majority of the people affected by sickle cell disease and beta-thalassemia won’t be able to afford this treatment. Still, Vertex was quick to defend its pricing by comparing it to the cost of a lifetime of treatment for a sickle cell disease patient. A lifetime of treatment for a patient with severe sickle cell disease can cost $4 million, and go up to $6 billion. On the other hand, a lifetime of treatment for a beta thalassemia patient ranges from $5 million to $7 million. This is the argument that the two companies plan to present to health insurers, hoping to persuade them to reimburse Exa-cel. But, this won’t be an easy process, since health insurers are usually skeptical of new treatments and need to confirm whether patients will be cured, or if they may have to be re-treated down the line. Despite these issues, Exa-cel still offers a good opportunity for Vertex, as there are 100,000 patients suffering from sickle cell disease in the U.S., and around 20 million other patients worldwide. Even if Vertex and CRISPR treat just 1% of this 20 million population, they’d gain $400 billion in sales of Exa-cel. The two companies intend to market Exa-cel globally and have already secured approval for the treatment in Saudi Arabia, Bahrain, and the UK. European Commission Approval Exa-cel aside, there’s another catalyst that could contribute to the company’s future growth. Vertex’s best-selling drug, Trikafta, and another drug called Kalydeco recieved approval in November 2023 from the European Commission for treatment of children ages 2 to 5 with cystic fibrosis. Thanks to this approval, both drugs will now have a much wider market in Europe. VRTX Stock Forecast Expecting VRTX to match the success of Purdue Pharma with OxyContin is unrealistic, however VX-548 could add notable revenue growth to the company given the market for painkillers and the search for a non-addictive alternative. As is, the company plans to apply for FDA approval for its painkiller by the middle of 2024, which could be a huge catalyst if the FDA gives VX-548 the green light. The announcement that VX-548 had passed two Phase 3 trials sent VRTX stock to its 52-week high, and FDA approval could push VRTX stock to new highs. Looking at the daily timeframe, VRTX has been in an uptrend since 2022 – increasing 104% over this period. This steady growth is another reason to be bullish on VRTX. Other catalysts like additional revenues from Exa-cel if health insurers agree to provide coverage for it and approval for Trikafta and Kalydeco by the European Commision are other reasons to be bullish on VRTX stock even if VX-548 does not recieve FDA approval.
NASDAQ:VRTX
by Penny_Stocks_Today
Stock of the Month: Vertex (VRTX)Our portfolio is up by more than 15% in the month of November. We are strictly following Mark Minervini's Trading Methodology. Here is a quick summary: Mark Minervini's trading methodology, often encapsulated in his SEPA (Specific Entry Point Analysis) system, is a comprehensive approach to trading that emphasizes the importance of timing, risk management, and stock selection. Here’s a concise summary: Trend Template: Minervini looks for stocks in a strong uptrend, using specific criteria for moving averages and price action to determine the health of the trend. Volatility Contraction Pattern (VCP): He identifies stocks undergoing a VCP, a series of tightening price consolidations which often precede a significant breakout. Risk Management: He sets strict stop-loss orders to limit potential losses, often using a maximum risk threshold per trade to manage overall portfolio risk. Buy Points: Minervini waits for a proper pivot point before entering a trade, ensuring the stock is moving on high volume out of a sound base pattern. Leadership: Preference is given to market leaders, stocks that outperform the market with strong earnings growth, sales, return on equity, and profit margins. Market Direction: He trades in harmony with the overall market direction, increasing exposure during bull markets and preserving capital during bear markets. By focusing on these key principles, Minervini aims to capture significant trends, minimize losses, and compound gains efficiently. Remember, this strategy requires discipline, continuous learning, and the ability to adapt to changing market conditions. Stock of the Month November: Vertex Detailed Technical Analysis Price and Moving Averages : The price of VRTX has recently experienced a bullish breakout. It is trading above all key moving averages (MA), including the 50-day, 100-day, and 200-day MAs, which are aligned in ascending order—a bullish signal known as a 'golden cross'. The 50-day MA is often used as a short-term trend indicator, and its position above the longer-term MAs suggests a strong upward trend. Volume : There's a noticeable increase in volume accompanying the price rise, which is a positive sign as it indicates strong buying interest. Moving Average Convergence Divergence (MACD): The MACD line is above the signal line and above zero, which is bullish. The histogram is showing increasing momentum to the upside. Relative Strength Index (RSI): The RSI is above 70, which typically indicates overbought conditions. However, in strong trends, the RSI can remain overbought for extended periods. IBD Ratings: The IBD (Investor's Business Daily) ratings show a high relative strength rating of 93, suggesting that the stock is outperforming 93% of all other stocks in terms of price performance. Bollinger Bands: The price has moved towards the upper Bollinger Band, which could signal that the stock is overextended in the short term. Support and Resistance: The chart shows previous resistance around the $360 level, which appears to have been decisively breached and may now serve as support. Candlestick Analysis: The recent candlesticks show strong bullish bodies, which confirms the buyers' control. Price Targets: If you're using chart patterns for price targets, the recent breakout suggests a continuation of the uptrend. Potential Risks: The overbought RSI readings could indicate a potential pullback or consolidation in the near term. Additionally, the elevated volume on up days should be monitored to ensure it doesn't start declining, which could signal a weakening trend. Here is a link top our updated portfolio: www.tradingview.com
NASDAQ:VRTX
by JS_TechTrading
Vertex’s Stock Heads for All-Time HighVertex Pharmaceuticals Inc. shares were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine. The stock jumped more than 10% Wednesday morning, on pace for its largest percentage gain in more than three years, and was set to cross the $100 billion market-capitalization threshold for the first time. The company’s experimental pain medicine VX-548 produced statistically significant, clinically meaningfully reductions in pain intensity in people with diabetic peripheral neuropathy, a type of nerve damage that can affect people with diabetes, Vertex said in a release. The pain control seen with the drug appears comparable to the “gold standard” pain medicine pregabalin, which is marketed by Viatris Inc. under the brand name Lyrica, Evercore ISI analyst Liisa Bayko wrote in a report Wednesday. Evercore analysts raised their price target on Vertex shares to $405, from $389 previously. The new data on the pain medicine “looks at least as good as or better than investor expectations,” Jefferies analysts said in a note Wednesday. Vertex is working to quickly advance the treatment to Phase 3 studies in diabetic peripheral neuropathy, Vertex’s chief medical officer, Dr. Carmen Bozic, said in a statement. Phase 3 results from a trial of the drug in acute pain are expected in the first quarter of next year. Vertex shares have gained 37% in the year to date, while the S&P 500 is up 21%. NASDAQ:VRTX is trading above the 50, 100 & 200-day Moving Averages indicating the trend might continue.
NASDAQ:VRTXLong
by DEXWireNews
Vertex Pharmaceuticals: Riding the Bullish Wave with a Bull Put In the world of trading, there are a variety of strategies that investors can employ to maximize their returns. One such strategy that has gained popularity in recent years is the vertical spread bull put. This strategy involves buying a put option with a lower strike price and selling a put option with a higher strike price. Understanding Vertical Spread Bull Puts A vertical spread bull put is a type of options trading strategy that involves simultaneously buying and selling put options with different strike prices. The strategy is designed to benefit from a rise in the underlying stock price. Benefits of Vertical Spread Bull Puts Vertical spread bull puts offer several advantages to traders, including: Limited risk: The maximum loss on a vertical spread bull put is limited to the difference between the strike prices minus the premium paid for both options. Limited capital requirement: The trader only needs to invest the premium for both options, which is typically lower than the cost of purchasing a single option. Potential for high reward: If the underlying stock price rises significantly, the trader can profit significantly. Vertex Pharmaceuticals: A Potential Opportunity Vertex Pharmaceuticals (VRTX) is a biotechnology company that develops innovative medicines for the treatment of serious diseases. The company's stock price has been on an upward trend in recent months, and there is potential for further growth. Using Vertical Spread Bull Puts on VRTX A vertical spread bull put on VRTX could be a profitable trading strategy. For example, a trader could buy a put option with a strike price of $320 and sell a put option with a strike price of $310. The options would expire on January 19, 2024. Potential Profit If the VRTX stock price rises above $320 by January 19, 2024, the trader will keep the premium from both options, which will be a profit. Potential Loss If the VRTX stock price falls below $310 by January 19, 2024, the trader will lose the premium paid for both options. Conclusion Vertical spread bull puts can be a profitable trading strategy for investors who believe that an underlying stock price will rise in value. With careful analysis and risk management, traders can use this strategy to maximize their returns. DISCLAIMER Do your research: Before entering into any options trade, it is crucial to conduct thorough research on the underlying stock and the market conditions. Manage your risk: Set stop-loss orders to limit your potential losses. Use technical analysis: Technical analysis can help you identify potential entry and exit points for your trade. Practice before you trade: Demo accounts can provide a safe environment to practice your trading strategies
NASDAQ:VRTX
by pietropaolog
2